Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8145094 | 0.90 | IDH1 (0.44) | LMNAGAAIDH1POLBMAOB | |
| SCHEMBL15910027 | 0.85 | LMNA (0.50) | LMNAGAAIDH1POLBMAOB | |
| SCHEMBL16921607 | 0.85 | LMNA (0.44) | LMNAGAAPOLBMAOBNPC1 | |
| SCHEMBL15910022 | 0.84 | LMNA (0.61) | LMNAGAAIDH1POLBMAOB | |
| SCHEMBL10290054 | 0.82 | LMNA (0.41) | LMNAGAAPOLBMAOBNPC1 | |
| SCHEMBL20218243 | 0.82 | TEAD4 (0.42) | LMNAGAAIDH1POLBMAOB | |
| SCHEMBL2592753 | 0.79 | LMNA (0.49) | LMNAGAAIDH1POLBMAOB | |
| SCHEMBL2115557 | 0.79 | IDH1 (0.50) | LMNAGAAIDH1POLBMAOB | |
| SCHEMBL2116063 | 0.79 | IDH1 (0.53) | LMNAGAAIDH1POLBMAOB | |
| SCHEMBL338697 | 0.79 | IDH1 (0.50) | LMNAGAAIDH1POLBMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-8673943-B2 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| US-20100098640-A1 | Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2010-04-22 | — | — | US | disclosed |
| US-6506911-B2 | Reacting a 2-(1-hydroxyalkyl)-3-hydroxypyran-4(1H)one compound with benzaldehyde dimethyl acetal to form 8-oxo-4,8-dihydro-2-phenyl-4h(3,2-d)-m-dioxin, reacting it with an amine compound to form an intermediate, then reducing | BTG INTERNATIONAL LIMITED (GB) | 2003-01-14 | — | — | US | disclosed |
| EP-0984934-B1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNAT LTD COMPANY NO 26 (GB) | 2003-01-08 | — | — | EP | disclosed |
| US-6476229-B1 | Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide | APOTEX, INC. (CA) | 2002-11-05 | — | — | US | disclosed |
| US-6472532-B1 | INEXPENSIVE METHOD USING KOJIC ACID AS SAFE STARTING MATERIAL FOR SYNTHESIS OF ORALLY ACTIVE IRON CHELATORS | APOTEX, INC. (CA) | 2002-10-29 | — | — | US | disclosed |
| US-6448273-B1 | SUCH AS 2,6-DIMETHOXYMETHYL-1-METHYL-3-BENZYLOXPYRIDIN-4(1H)-ONE; TREATING DISORDERS ASSOCIATED WITH IRON DISTRIBUTION AND IRON DEPENDANT PARASITES; REDUCED LEVELS OF ACTIVE AGENT; SELECTIVE TARGETING TO TISSUES AND LIVER; METABOLIC STABILITY | BTG INTERNATIONAL LIMITED (GB) | 2002-09-10 | — | — | US | disclosed |
| US-6426418-B1 | REACTING A 3-OXY-2-HYDROXYALKYL-4H-PYRAN-4-ONE DERIVATIVE WITH SODIUM HYPOCHLORITE SOLUTION, POTASSIUM BROMIDE, TEMPO, AND A PHASE TRANSFER CATALYST TO PRODUCE A 3-OXY-2-CARBOXY-4H-PYRAN-4-ONE DERIVATIVE | APOTEX, INC. (CA) | 2002-07-30 | — | — | US | disclosed |
| US-20020068758-A1 | Novel orally active iron (III) chelators | BTG INTERNATIONAL LIMITED. | 2002-06-06 | — | — | US | disclosed |
| US-6335353-B1 | 3-HYDROXYPYRIDIN-4-ONE DERIVATIVE; IRON DEFICIENCY ANEMIA AND THALASSEMIA TREATMENT | BTG INTERNATIONAL LIMITED (GB) | 2002-01-01 | — | — | US | disclosed |
| EP-0984934-A1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNATIONAL LIMITED (Company No. 2664412) (GB) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054138-A1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNATIONAL LIMITED (GB) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068758-A1 | Novel orally active iron (III) chelators | HAMP, HRH2, GRHPR | LMNA 2634/4885GAA 1367/4885IDH1 808/4885 |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | SLC40A1, TFRC, FECH | LMNA 2643/4885GAA 212/4885IDH1 239/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | LMNA 2945/4885GAA 1442/4885IDH1 147/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | LMNA 2945/4885GAA 1442/4885IDH1 147/4885 |
| US-20100098640-A1 | Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation | DNM1, BET1, FOLH1 | LMNA 2576/4885GAA 594/4885IDH1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.